FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).

FG-3019 (30 mg/kg; i.p. every 3 d for 9 d) 与 Gemcitabine 联合使用可显着降低小鼠胰腺导管腺癌 (PDA) 的生长，并诱导 LSL-Kras^G12D/+;LSL-Trp53^R172H/+;Pdx-1-Cre (KPC) 小鼠中的肿瘤细胞凋亡。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

FG-3019 (30 mg/kg; i.p. every 3 d for 9 d) 与 Gemcitabine 联合使用可显着降低小鼠胰腺导管腺癌 (PDA) 的生长，并诱导 LSL-Kras^G12D/+;LSL-Trp53^R172H/+;Pdx-1-Cre (KPC) 小鼠中的肿瘤细胞凋亡。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.  [Content Brief]

  . Neesse A, et, al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30.  [Content Brief]